Exceeding Financial Expectations
Evolent reported Q3 financial results that exceeded expectations on both the top and bottom line, with revenue reaching $479.5 million, at the top of their guidance range.
New Revenue Arrangements
Two new revenue arrangements were announced: a contract with a major Blue Cross plan expected to contribute over $500 million annually, and another with a large provider-sponsored health plan in the Southwest, adding to a total revenue under contract for 2026 of approximately $2.5 billion.
Margin Expansion
Q3 adjusted EBITDA was $39 million, representing 23% growth year-over-year, with over 90% of Performance Suite revenue in 2026 expected to be covered by enhanced protections.
Strategic Partnerships and Product Development
Strategic partnership with American Oncology Network and progress in comprehensive cancer care navigation program, showing decreases of up to 40% in inpatient and emergency department utilization.